Methods: Time-growth studies were performed with approximately 1×10 5 cfu/mL of Acinetobacter baumannii or Pseudomonas aeruginosa at baseline. Serial samples were obtained to quantify the bacterial burden over 24 h. The growth rates (K g ) of isogenic strains (antibiotic susceptible and resistant) were determined individually and used to predict their relative abundance in a co-culture over an extended period of time. The predicted difference between the two strains was subsequently validated by in vitro growth competition experiments.
Introduction
Antimicrobial resistance is a serious problem in healthcare settings; it is an important cause of increased morbidity and mortality. 1 -3 Drug resistance in bacteria can be associated with a biological fitness cost. It has been proposed that the magnitude of this cost is the primary factor that influences the rate of resistance development, the stability of the resistance, and the rate at which the resistance might decrease if antibiotic use were reduced. 4 -6 The fitness cost associated with drug resistance is often determined by competition experiments between isogenic strains (antibiotic susceptible and resistant) in culture media or laboratory animals. Individual strains are mixed at a certain ratio (usually 1: 1) and repeatedly transferred into fresh growth media/animals after each cycle of competitive growth. At every cycle, the numbers of total and resistant cells are determined by plating aliquots onto non-selective and drugsupplemented plates, respectively. The relative fitness is expressed as the competition index, calculated as the ratio of bacterial burdens between the resistant and susceptible strains at the end of an experiment, divided by the same ratio at baseline. The selection coefficient is used to estimate the relative fitness of the two competitors over the entire competition experiment. 7 Despite being commonly used in many studies, this approach is time consuming and labour intensive. To determine the difference in fitness between two strains, numerous (often more than 50) generations of co-culture are conducted in a competition experiment. 7 The experiment duration may be even longer if only a slight fitness difference exists between two strains.
An alternative method was developed to assess fitness cost in drug-resistant bacteria. To illustrate our approach, we determined the growth rates of the wild-type and their isogenic resistant mutant strains of Acinetobacter baumannii and Pseudomonas aeruginosa. A simple mathematical model based on growth rates was developed to quantitatively predict the fitness cost of drug resistance. An efficient method to estimate # The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2012; 67: 928 -932 doi:10.1093/jac/dkr560 Advance Access publication 9 January 2012 biofitness cost could help us to anticipate the evolution, dissemination and reversion of drug resistance.
Materials and methods

Microorganisms
A wild-type strain of A. baumannii ATCC BAA 747 (ATCC, Rockville, MD, USA) and its spontaneous isogenic mutant strain AB AR3 (recovered from an exposure to amikacin) were used in the study. 8 The MICs of amikacin for AB BAA 747 and AB AR3 were previously found to be 2 and 24 mg/L, using a broth dilution method recommended by the CLSI. 9 In addition, a laboratory strain of P. aeruginosa PAO1 and its isogenic daughter strain PAO1DmexRDoprD were studied. 10 The levofloxacin MICs for the isolates were 0.25 and 1.5 mg/L, respectively. The bacteria were stored at 2708C in Protect w (Key Scientific Products, Round Rock, TX, USA) storage vials. Fresh isolates were subcultured twice on 5% blood agar plates (Hardy Diagnostics, Santa Maria, CA, USA) for 24 h at 358C prior to each experiment. It was assumed that fitness loss was not reversible after antibiotic pressure was removed.
In vitro time-growth studies
The in vitro growth rates of AB BAA 747 and AB AR3 were determined individually in full-strength and 0.1-strength cation-adjusted MuellerHinton broth (Ca-MHB) (BBL, Sparks, MD, USA). For PAO1 and PAO1DmexR-DoprD, assessment was conducted in full-strength Ca-MHB only. Briefly, 1 -2 medium-sized fresh colonies were inoculated in Ca-MHB until reaching log-phase growth. The bacterial suspension was then diluted based on absorbance at 630 nm and transferred to a 50 mL flask containing 20 mL of Ca-MHB in different strengths. The final inoculum at baseline was approximately 1×10 5 cfu/mL. The experiment was conducted for 24 h in a shaker water bath at 358C. Serial samples (baseline, 1, 2, 3, 4, 6, 8 and 24 h) were obtained in triplicate, and bacterial burden was determined by quantitative culture after 10× serial dilutions. Colony counts were enumerated after incubation at 358C in a humidified incubator for up to 24 h. The theoretical lower limit of detection was 100 cfu/mL.
Mathematical modelling and prediction of in vitro growth
The exponential growth of a bacterial population was analysed using a mathematical model. Details of the model were described elsewhere. 10 The mean and 95% confidence range of each bacterial growth rate constant (K g ) value were derived. The K g values of the wild-type and mutant strains were used to predict their relative abundance in a co-culture over an extended period of time. The equation used for prediction was
where N wt and N m refer to the sizes of the bacterial population of wildtype and mutant strains at time t, and K g wt and K g m are the growth rate constants of corresponding strains, respectively. Details of the formula derivation are available as Supplementary data at JAC Online. As the above equation represents non-saturable growth conditions, an efficiency factor was considered based on the time in which bacteria were deemed to be in exponential growth. It was expressed as a percentage of the competition cycle in which the bacteria were growing exponentially before reaching saturation. The predicted range of difference between two strains over time was subsequently validated by in vitro growth competition experiments.
In vitro growth competition experiments
The in vitro growth competition between two A. baumannii strains was assessed in full-strength and 0.1-strength Ca-MHB, and the experiment for the P. aeruginosa strains was performed in full-strength Ca-MHB. Bacterial inocula of the wild-type and mutant strains were prepared as described above. The bacteria were transferred to a flask containing 10 mL of fresh pre-warmed Ca-MHB. The initial inocula of both strains were approximately 1×10 5 cfu/mL and they were grown in a shaker water bath at 358C. After each 12 h competition cycle, 10 mL of mixed bacterial suspension in the competition flask was transferred to a flask with 10 mL of fresh pre-warmed Ca-MHB. Serial samples were obtained in triplicate every 24 h and bacterial burdens were determined by quantitative culture on drug-free Mueller -Hinton agar (MHA) plates (BBL) (for total bacterial burden) and drug-supplemented MHA plates (8 mg/L amikacin for the A. baumannii mutant strain or 1 mg/L levofloxacin for the P. aeruginosa mutant strain). The plates were incubated at 358C in a humidified incubator for up to 24 h (drug-free plates) and 48 h (drugsupplemented plates) before counting. The bacterial burdens of the wild-type strain were derived from the difference in colony counts between drug-free plates and drug-supplemented plates. The relative proportion of both strains over time was used to validate the model.
Results
In vitro time-growth studies
The in vitro growth rate constants of AB BAA 747, PAO1 and their mutant strains in full-strength and 0.1-strength Ca-MHB are shown in Table 1 . In both strains of A. baumannii, the growth rate constant values were similar in different strengths of broth, indicating that bacterial growth was not considerably impacted by nutrient depletion. The growth rates of P. aeruginosa are also shown in Table 1 .
The time to reach non-exponential growth in different strengths of broth was similar. The observed time for growth saturation was 3 h for AB BAA 747 and 6 h for AB AR3. The growth rate of the mutant was approximately half of that of the parent wild-type strain. The mutant P. aeruginosa strain also had a relatively slower growth rate than the parent wild-type. The time to non-exponential growth for PAO1 and its mutant were both approximately 8 h.
Mathematical modelling and prediction of in vitro growth
As the growth rates of AB BAA 747 or AB AR3 were not significantly different in different strengths of broth, we used the K g Prediction of bacterial fitness cost 929 JAC values derived from full-strength Ca-MHB to predict the relative proportional change of the two strains over time (Figure 1 ). In view of the time for AB BAA 747 observed to be in nonexponential growth, an efficiency factor of 25% (3 h/12 h) was applied in the model predictions. Similarly, K g values of the P. aeruginosa strains and an efficiency factor of 67% (8 h/12 h) were used in the prediction of growth competition (shown in Figure 2 ).
In vitro growth competition experiments
The in vitro growth competition results between the wild-type and mutant strains of A. baumannii in full-strength and 0.1-strength Ca-MHB are shown in Figure 3 . The curves had a similar trend, indicating that different strengths of broth had little impact on the growth competition, consistent with our findings in time-growth studies. With successive competition cycles, the relative proportion of the mutant in the overall population decreased significantly. The difference between the two strains was approximately 8 and 7 log cfu/mL in full-strength and 0.1-strength broths after 96 h, respectively. These results suggested that a substantial fitness cost was associated with amikacin resistance in this isolate. The competition experiments were terminated prematurely (at 96 h) in view of the considerable difference between the two strains observed and the fact that the lower limit of reliable detection had been reached. Compared with A. baumannii, the relative difference in bacterial burden observed in the two P. aeruginosa strains was less pronounced. The difference between the two strains was approximately 3.7 log cfu/mL after 144 h (shown in Figure 4) . The difference in bacterial burden observed in competition studies was in general agreement with the difference in the K g values. The greater the difference in growth rate constant between two strains, the greater the bacterial burden difference over time. The correlations between predicted and observed changes in bacterial burden over time are shown in Figure 1 
Discussion
Drug resistance usually engenders a reduction in biological fitness because antibiotics target basic and important bacterial functions such as cell wall synthesis, regulation of chromosome supercoiling, RNA transcription and protein synthesis. However, mutants with no measurable cost have also been observed. 11, 12 Studies have proposed that environmental conditions affect fitness cost, and the cost of drug resistance can be reduced by regulation of the resistance mechanism or cost compensation. 13 -15 As a biological phenomenon closely correlated with drug resistance, various fitness studies have been undertaken in vitro, in laboratory animals and in humans. 11, 16, 17 The cost of resistance is most commonly measured by pair-wise competition experiments. There are several limitations of estimating the resistance cost using competition experiments. First is the interpretation of negative results. Some mutants are found to be cost-free relative to the wild-type strain in competition experiments. However, it is uncertain if these are true 'no cost' mutants, as a difference of ,1% is difficult to detect by the above method. 18 Another limitation is the long duration and intensive labour requirement in these experiments. In most competition experiments, growth medium is incubated overnight (24 h) to complete one cycle of competition. At least five successive competition cycles are necessary in each experiment.
6,7 The duration of the experiment required would be several times more for some bacteria of long doubling time, especially Mycobacterium tuberculosis and Borrelia burgdorferi.
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To circumvent limitations of the common methodology, we developed a simple mathematical model characterizing the relative bacterial growth over time, which was used to predict the fitness cost of drug resistance. The in vitro time-growth studies are relatively easy to perform in growth media. The duration of the experiment was as short as growth until the stationary phase, and 24 h will be the routine duration for most bacteria. The growth rate constants of both isogenic strains were estimated and then used in the prediction model. The predicting ability of the model was validated by the conventional in vitro competition experiments using two bacterial species. We found the model to be reasonably accurate in assessing resistance cost.
As the relative bacterial burden over time correlated with the difference in growth rate constants, the magnitude of the difference between isogenic strains could be used to infer the extent of fitness cost (i.e. the greater the growth rate difference, the greater the fitness cost associated with resistance). Furthermore, a relatively short duration would be sufficient to determine the fitness difference in strains with considerable growth rate differences. Our experimental data suggest that the proposed model was general and not genus specific. The growth rate difference was higher in the A. baumannii strain pair. Experimentally, a greater difference in bacterial burden difference was observed in A. baumannii compared with P. aeruginosa. For the A. baumannii strains, a .7 log cfu/mL difference was observed after only 96 h co-culture (Figure 3) , while it took 144 h for P. aeruginosa strains to reach close to a 4 log cfu/mL difference (Figure 4 ).
There were several limitations in the study. The model focused on capturing exponential growth. The prediction performance of the model is unclear if investigated strains have a significantly long lag phase. As the bacterial burden approached the theoretical lower limit of detection (2 log cfu/mL), the difference between the two strains could be less reliable. This would result in a slight bias over time (as shown in Figure 1 beyond 72 h). In addition, only two representative Gram-negative bacteria were examined. Further studies in other clinically important pathogens (e.g. Staphylococcus aureus and Streptococcus pneumoniae) could further validate the utility of the proposed mathematical model. Finally, virulence (loss) associated with drug resistance was not taken into consideration by our modelling approach.
In conclusion, our model was reasonable in characterizing bacterial growth and predicting the fitness cost of resistance.
The new method appears simple and robust in the assessment of in vitro fitness cost associated with drug resistance. Further investigations on the in vivo relevance of the model are warranted.
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